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What is the central question of this study? 
Duchenne muscular dystrophy (DMD) is associated with severe muscle weakness, with 
inflammation recognised as a contributing factor to DMD pathology. We have previously 
reported impaired upper airway dilator muscle function in the mdx mouse model of DMD. 
Our aim was to assess the effect of blocking interleukin-6 receptor signalling and stimulating 
corticotrophin releasing factor receptor 2 signalling on mdx sternohyoid muscle structure and 
function.  
What is the main finding and its importance? 
The combined anti-inflammatory and anti-stress interventional treatment had a positive 
inotropic effect on sternohyoid muscle force, restoring mechanical work and power to wild 
type values. Furthermore, drug treatment reduced myofibre central nucleation and preserved 
the MHC type IIb fibre complement of mdx sternohyoid muscle. These data may have 
implications for the development of pharmacotherapies for DMD with relevance to 
respiratory muscle performance. 
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Abstract 
The mdx mouse model of Duchenne muscular dystrophy (DMD) shows evidence of impaired 
pharyngeal dilator muscle function. We hypothesised that inflammatory and stress-related factors are 
implicated in airway dilator muscle dysfunction. Six week old mdx (n=26) and wild-type (WT; n=26) 
mice received either saline (0.9% w/v) or a co-administration of neutralising IL-6 receptor 
antibodies (xIL-6R; 0.2 mg/kg) and corticotrophin releasing factor receptor 2 agonist (Urocortin 
2; 30μg/kg) over 2 weeks. Sternohyoid muscle isometric and isotonic contractile function was 
examined ex vivo. Muscle fibre centronucleation, and muscle cellular infiltration, collagen content, 
fibre type distribution and fibre cross-sectional area were determined by histology and 
immunofluorescence. Muscle chemokine content was examined by use of a multiplex assay. 
Sternohyoid peak specific force at 100Hz was significantly reduced in mdx compared with WT. Drug 
treatment completely restored force in mdx sternohyoid to WT levels. The percentage of centrally-
nucleated muscle fibres was significantly increased in mdx and this was partially ameliorated 
following drug treatment. The areal density of infiltrates and collagen content were significantly 
increased in mdx sternohyoid; both indices were unaffected by drug treatment. The abundance of 
MHC type IIb fibres was significantly decreased in mdx sternohyoid; drug treatment preserved MHC 
type IIb complement in mdx muscle. The chemokines MIP-2, IP-10 and MIP-3α were significantly 
increased in mdx sternohyoid compared with WT. Drug treatment significantly increased chemokine 
expression in mdx but not WT. Recovery of contractile function was impressive in our study with 
implications for DMD. The precise molecular mechanisms by which the drug treatment exerts an 
inotropic effect on mdx sternohyoid muscle remains to be elucidated.  
Keywords 
DMD, mdx, interleukin-6, stress, corticotrophin releasing factor, sternohyoid muscle. 
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1. Introduction 
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that occurs in 1:3,500 male 
births (Emery, 1991). Patients have defects in the dystrophin gene, which results in a lack of the 
structural protein dystrophin (427 kDa). Dystrophin is a rod-shaped protein expressed in skeletal, 
cardiac and smooth muscle, where it links cytoskeleton actin to the sarcolemma and has a 
physiological role in preventing damage during muscle contraction (Nowak & Davies, 2004). The 
absence of dystrophin in DMD induces severe damage to muscle fibres, with resultant inflammation 
(Deconinck & Dan, 2007). As the disease progresses there is a loss of functional muscle fibres due to 
necrosis and the deposition of fibrotic and adipose tissue prevails, resulting in muscle weakness.  
The respiratory system is severely impaired in DMD due to respiratory and abdominal muscle 
weakness, as well as scoliosis (De Bruin et al., 1997; Beck et al., 2006). DMD is a progressive 
disease and thus respiratory function deteriorates with age, with patients often presenting with 
reduced vital capacity and breathing disturbances such as hypoventilation and sleep-disordered 
breathing (SDB) (Smith et al., 1989; Hill et al., 1992; Barbé et al., 1994). While the diaphragm has 
been the focus of many studies in this field, there is a paucity of information pertaining to the upper 
airway muscles controlling airway calibre and collapsibility, thereby facilitating breathing (White & 
Younes, 2012). The prevalence of obstructive sleep apnoea (OSA) in DMD (Suresh et al., 2005), 
suggests that upper airway muscle dysfunction, and poor control of airway patency during sleep, 
potentially contributes to breathing disturbances in DMD. 
The mdx mouse is the most widely studied animal model of DMD. We have previously reported 
respiratory dysfunction, which presents at an early age in the mdx mouse (8 weeks), consisting of 
hypoventilation and upper airway (sternohyoid) muscle weakness (Burns et al., 2015; Burns & 
O'Halloran, 2016). In human patients and mdx mice, functional impairments are driven by 
pathological changes in skeletal muscles due to dystrophin deficiency, including fibre degeneration 
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and necrosis, with inflammation thought to play an integral part in DMD muscle pathology 
(Deconinck & Dan, 2007).  
In patients and mdx mice, sarcolemmal damage is accompanied by the infiltration of immune cells, 
primarily macrophages and T cells, a key source of inflammatory cytokines (Moran & Mastaglia, 
2014). These molecules mount an inflammatory response through activation of additional cytokines 
and recruitment of further immune cells to the damaged muscle (Villalta et al., 2015). Immune cells 
are not the only source of cytokines, with damaged muscles fibres also serving as a contributory factor 
(Whitham & Febbraio, 2016). In DMD, the heightened expression of pro-inflammatory cytokines 
such as tumour necrosis factor alpha (TNF-α) and interleukins (IL)-1 and -6, are early disease 
indicators and are associated with exacerbation of the inflammatory response in dystrophic muscle 
(Evans et al., 2009b, a). IL-6 is released from a variety of tissues including immune cells and 
adipocytes and is commonly referred to as a myokine as it can be secreted from muscle in response to 
physical activity (Jonsdottir et al., 2000; Pedersen & Febbraio, 2008). This inflammatory cytokine is 
of particular interest in DMD pathology since it is elevated in muscle and plasma samples from DMD 
patients (Messina et al., 2011; Rufo et al., 2011; Pelosi et al., 2015a) and mdx mice (Pelosi et al., 
2015a). IL-6 is pleiotropic, however it mediates its pro-inflammatory effects via its trans-signalling 
pathway by use of the soluble IL-6 receptor (IL-6R) (Pedersen & Febbraio, 2008). Its importance in 
mdx skeletal muscle pathology was recently highlighted (Pelosi et al., 2015a), showing that blockade 
of IL-6 signalling in mdx mice has beneficial functional outcomes in dystrophic skeletal muscle.  
Muscle wasting is a common feature of DMD due to muscle proteolysis, thus pharmacological 
interventions aimed at rescuing muscle are attractive. Corticotrophin releasing factor receptor 2 
(CRFR2) agonists have been shown to modulate muscle mass through the activation of anabolic 
signalling pathways and a capacity to alter the rate of proteolysis during atrophying conditions (Hall 
et al., 2007). In addition, CRFR2 can reduce nerve damage, corticosteroid-induced atrophy and loss of 
muscle mass due to immobilisation (Hinkle et al., 2003). The CRFR2 agonist, Urocortin 2 (Uro-2), 
has been shown to improve diaphragm function and reduce fibrosis and immune cell infiltration in 
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mdx mice (Reutenauer-Patte et al., 2012). Recent work demonstrated that neutralisation of IL-6 
receptor (xIL-6R) or stimulation of CRFR2 both had positive inotropic effects on the major pump 
muscle of breathing – the diaphragm (Manning et al., 2017). Furthermore, Manning et al. (2017) 
reported that co-treatment of xIL-6R and Uro-2 had an additive inotropic effect on diaphragm muscle 
force. We hypothesised that co-administration of xIL-6R antibodies and Uro-2 alleviates upper airway 
muscle weakness in dystrophin deficient mdx mice. We sought to examine structure and function of 
sternohyoid muscle (pharyngeal dilator) from age-matched wild type (WT) and mdx mice following 
saline or combined xIL-6R and Uro-2 drug treatment.  
2. Methods 
2.1 Ethical approval 
All procedures were performed under licence in accordance with National and European guidelines 
following local research ethics committee approval. 
2.2 Animals 
Male and female wild type (WT; C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmd
mdx
/J) mice were 
purchased from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME) and were bred in our 
institution’s animal housing facility. Animals were housed conventionally in a temperature- and 
humidity-controlled facility, operating on a 12 h light: 12 h dark cycle with food and water available 
ad libitum. 6 week old male WT and mdx mice received a treatment consisting of a co-administration 
of xIL-6R (IL-6R neutralising antibody; MR1-61 (Okazaki et al., 2002); 0.2 mg/kg) and Uro-2 
(CRFR2 agonist; 30 μg/kg; U9507, Sigma Aldrich, Wicklow, Ireland) or saline (vehicle control; 0.9% 
w/v). MR1-61 stock was kept at -80
o
C and Uro-2 stock at -20
o
C. A working solution containing both 
MR1-61 (26.7µg/ml) and Uro-2 (4µg/ml) was made in sterile saline, aliquoted and stored at -20
o
C 
until day of injection. Doses and treatment protocol were chosen based on previous studies (Manning 
et al., 2016, 2017). Treatment consisted of six sub-cutaneous injections to the scruff of the neck on 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
alternate days over the course of two weeks beginning at 6 weeks of age. A 20g mouse received an 
injection bolus of 150μl. WT and mdx animals were assigned at random to saline or drug treatment, 
establishing 4 groups: WT saline (21.4 ± 1.6g; n=13), WT treatment (22.0 ± 1.2g; n=13), mdx saline 
(24.4 ± 1.6g; n=13) and mdx treatment (24.5 ± 1.7g; n=13). Animals were anaesthetised with 5% 
isoflurane by inhalation in oxygen and euthanised by cervical dislocation. 
2.3 Muscle physiology 
2.3.1 Ex vivo muscle preparation 
The sternohyoid muscles were immediately excised and placed in a tissue bath at room temperature 
containing continuously gassed hyperoxic (95% O2/ 5% CO2) Krebs solution (NaCl 120 mM, KCl 
5mM, Ca
2+
 gluconate 2.5 mM, MgSO4 1.2 mM, NaH2PO4 1.2 mM, NaHCO3 25mM, glucose11.5mM) 
and D-tubocurarine (25μM). The paired sternohyoid muscles were carefully separated along a natural 
division in the midline. One half was used immediately for functional analysis and the other half was 
snap frozen in liquid nitrogen for subsequent molecular analysis (section 2.5). A single longitudinal 
muscle strip (2mm in diameter) for each animal was studied in a water-jacketed muscle bath, 
containing Krebs solution, maintained at 35
o
C gassed with 95% O2/ 5% CO2. Each muscle strip was 
placed between a pair of platinum plate electrodes, with the caudal end fixed to an immobile hook and 
the rostral end attached to a dual-mode lever transducer system by non-elastic string. Muscle 
preparations were allowed a 5 min equilibration period. 
2.3.2 Isometric protocol 
Following equilibration, the optimum length (Lo) was determined by adjusting the position of the 
force transducer by use of a micro-positioner between intermittent twitch contractions. The Lo was 
taken as the muscle length associated with maximal isometric twitch force in response to single 
isometric twitch stimulation (supramaximal stimulation, 1ms duration). Once Lo was determined, the 
muscle stayed at this length for the duration of the protocol. A single isometric twitch was measured. 
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Peak isometric twitch force, contraction time (CT; time to peak force) and half relaxation time (½ RT; 
time for peak force to decay by 50%) were determined. Next, an isometric tetanic contraction was 
elicited by stimulating muscle strips with supramaximal voltage at 100 Hz for 300 ms duration. Peak 
isometric tetanic force was determined at 100Hz (O'Halloran, 2006; Burns & O'Halloran, 2016). 
2.3.3 Isotonic protocol 
Following the isometric protocol, concentric contractions were elicited in incremental steps with 
varying load (0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 60%; % of force at 100Hz) with 30 s 
rest between each contraction. Muscle length returned to Lo following each contraction. Total 
shortening was determined as the maximum distance shortened during contraction. Shortening 
velocity was determined as the distance shortened during the initial 30 ms of shortening (Lewis et al., 
2015; Lewis et al., 2016). Mechanical work (force x total shortening) and power (force x shortening 
velocity) were determined at each step of the incremental load step test (Lewis et al., 2015; Williams 
et al., 2015; Burns & O'Halloran, 2016; O'Leary & O'Halloran, 2016). 
 
2.4 Muscle immunohistochemistry and histology 
2.4.1 Tissue preparation 
The sternohyoid muscles were excised and divided down the midline; one half was embedded in 
optimum cutting temperature (OCT) embedding medium and frozen in isopentane cooled in liquid 
nitrogen and stored at -80
o
C for subsequent structural analysis (n=4-5 per group). The other half of the 
muscle was placed in 4% paraformaldehyde overnight at 4
o
C before being transferred to 70% ethanol 
prior to tissue processing and paraffin embedding for histological analysis (n=4-5 per group). 
2.4.2 Myosin heavy chain fluorescence immunohistochemistry 
Serial transverse muscle sections (10 µm) were cryo-sectioned (Model CM30505; Leica 
Microsystems, Nussloch, Germany) at –22oC and mounted on polylysine-coated glass slides (VWR 
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International, Dublin, Ireland). Sections were captured from the middle belly and distal regions of the 
muscle. Slides were immersed in PBS (0.01 M) containing 1% bovine serum albumin (BSA) for 15 
minutes. After 3x5 minute PBS washes, slides were immersed in PBS containing 5% goat serum for 
30 minutes. Following a further 3x5 minute PBS rinses, slides were incubated with an unconjugated 
AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L) diluted in PBS (1:13, Jackson 
ImmunoResearch Labs) for 1 hour at room temperature, to enable the use of mouse monoclonal 
primary antibody staining on mouse tissue. After 3x2 minute washes in PBS, primary antibodies were 
applied. Primary monoclonal myosin antibodies were obtained from the Developmental Studies 
Hybridoma Bank (DSHB), University of Iowa, Iowa City, IA, USA and a rabbit anti-laminin antibody 
was obtained from Sigma-Aldrich (L9393). A triple-labelling approach was applied to tag MHC types 
I (BAD5, 1:100), IIa (sc71 1:100) and IIb (BFF3 1:100) on a single section. On a serial section, a 
double-labelling approach consisted of a rabbit anti-laminin antibody (1:500) and a pan-MHC 
antibody for the indirect determination of pure MHC IIx fibres, BF35 (1:50), labelling all MHC 
isoforms but IIx, enabling visualisation of IIx fibres by absence of staining; all antibodies were diluted 
in PBS and 1% BSA solution. Triple and double labelling solutions were applied on alternate sections 
on each slide. Individual sections were encircled with a hydrophobic pen (ImmEdgeTM Vector Labs) 
to prevent contamination from neighbouring sections on the same slide. Slides were incubated with 
the primary antibodies overnight at 4
o
C in a humidity chamber.  
After the incubation period, slides were washed with PBS for 3x5 minutes before the appropriate 
secondary antibodies were applied. All secondary antibodies were diluted in PBS and 1% BSA. For 
the triple-labelled slides, a cocktail of secondary antibodies was prepared containing AlexaFluor350-
conjugated goat anti-mouse IgG2b (1:500, Invitrogen, Biosciences Ltd, Dun Laoghaire, Ireland), 
Dylight594-conjugated goat anti-mouse IgG1 (1:500, Jackson ImmunoResearch Europe Ltd, Suffolk, 
UK) and AlexaFluor488-conjugated goat anti-mouse IgM (1:250, Invitrogen), targeting MHC I, IIa 
and IIb, respectively. Secondary antibodies for double-labelled sections were Dylight594-conjugated 
goat anti-mouse IgG1 (1:500, Jackson) and FITC-conjugated anti-rabbit secondary antibody (1:250, 
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Sigma-Aldrich). Secondary antibodies were applied and slides were incubated for 1 hour in the dark 
at room temperature. Slides were rinsed with PBS for 3x5 minutes, cover slipped with polyvinyl 
alcohol mounting medium with DABCO
®
 anti-fade (Sigma) before observation with a fluorescent 
microscope (Olympus BX51). Negative controls were also performed in which primary antibodies 
were omitted and sections were instead incubated in diluent. Images were merged using ImageJ 
software (W. S. Rasband, ImageJ; US National Institutes of Health, Bethesda, MD, USA). 
2.4.3 Histological Analysis 
Muscle samples were dehydrated (70% ethanol, 80% ethanol, 95% ethanol, 60 minutes each) and then 
placed in 100% ethanol (60 minutes x2). Samples were then cleared in xylene (60 minutes x2), before 
being transferred to two changes of paraffin (one hour each) (Leica TP1020, Histokinet). Tissue 
samples were then embedded in paraffin (Sakura Tissue-Tek TEC, Histolab Histowax embedding 
medium), and serial cross-sections (5 μm thick) were sectioned using a microtome (Leica RM2135). 
Serial sections were collected throughout the muscle (mid-belly and distal regions) onto glass slides 
and oven-dried (overnight at 37°C).  
To examine putative inflammatory cell infiltration, and central nucleation of muscle fibres, tissue 
sections were stained with haematoxylin and eosin (H&E). Tissue sections were deparaffinised in 
xylene (2 x 5 minutes each), rehydrated through a graded series of alcohols (100% ethanol, 95% 
ethanol, 70% ethanol, one minute each). Sections were stained with haematoxylin (Delafield’s 
Haematoxylin) (5 min) and subsequently rinsed in distilled H2O (5 min), stained in eosin (alcoholic 
Eosin-Y, Sigma Aldrich; 1 min), rinsed in distilled H2O, and dehydrated (70% ethanol, 95% ethanol, 
1 min each, 100% ethanol, 2 x 1 minute) and xylene (5 min). For collagen staining, a Masson’s 
trichrome protocol was followed (Sigma Aldrich). Slides were mounted using DPX mounting medium 
(Sigma Aldrich, USA), air-dried and visualised on a bright field microscope (Olympus BX51) x 20 
magnification.  
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
2.5 Molecular studies 
2.5.1 Tissue preparation 
Sternohyoid samples stored at -80
o
C were removed and allowed to defrost at 4
o
C for 5 minutes. All 
procedures were performed at 4
o
C to prevent protein degradation. Samples were homogenized in a 
lysis buffer (RIPA) made up from 10X RIPA, deionized water, 200mM sodium fluoride (NAF), 
100mM phenylmethylsulfonylfluoride (PMSF), protease cocktail inhibitor 1 and phosphatase cocktail 
inhibitor 2. Following the homogenization process, the reactant mixtures were centrifuged (14,000 x 
rpm) at 4
o
C for 20 min and the supernatants were harvested. Total amount of protein for each tissue 
sample was determined using Pierce ® Bicinchoninic Acid Assay (BCA assay, Thermo Scientific, 
Fisher, Dublin, Ireland). Supernatants were stored at -80
o
C for future use. 
2.5.2 Chemokines 
A chemokine assay (U-PLEX Chemokine Combo; K15099K-1, Meso Scale Discovery, Rockville, 
MD) was used to examine chemokines in sternohyoid muscle from all four groups: WT saline (n=7-
8), WT treatment (n=7-8), mdx saline (n=8) and mdx treatment (n=7). The assay was performed 
according to the manufacturer’s instructions using an extended incubation time to improve detection 
(the plate was incubated overnight at 4
o
C). Following incubation, the plate was read on QuickPlex SQ 
120 imager (Meso Scale Discovery, Rockville, MD). Signals within the detectable range were 
achieved with reliability for the following 3 chemokines: macrophage inflammatory protein 2 (MIP-
2), interferon-γ-induced protein 10 (IP-10) and macrophage inflammatory protein-3α (MIP-3α). 
 
2.6 Data and image analysis 
Specific force was calculated in N/cm
2
 of estimated muscle cross-sectional area (CSA). The CSA of 
each strip was determined by dividing the muscle mass (weight in grams) by the product of muscle Lo 
(cm) and muscle density (assumed to be 1.06 g/cm
3
). The CT and ½ RT were measured as indices of 
isometric twitch kinetics. For isotonic load relationships, data were plotted as the measured variable 
versus % load. Total muscle shortening was normalised to Lo and expressed in L/Lo. Similarly, 
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shortening velocity was normalised to Lo and expressed in Lo/s. Maximum total shortening (Smax) 
and maximum shortening velocity (Vmax) were measured when both were maximal at 0% load. 
Mechanical work was measured in J/cm
2
. Mechanical power was expressed in W/cm
2
. Maximum 
mechanical work (Wmax) and power (Pmax) were also measured and typically occurred between 
30% and 40% load. 
 
For MHC fibre type analysis, muscle sections were viewed at x10 magnification and images captured 
using an Olympus BX51 microscope and an Olympus DP71 camera. Cell Sens™ (Olympus) was used 
to digitally capture the images. Analysis was carried out using image J software, where fibre type 
CSA and fibre type distribution for each MHC fibre type were determined. CSA measurements were 
made by fibre “circling” based on MHC labelling. A square test frame (640,000 μm2) with inclusion 
and exclusion boundaries was employed to calculate these parameters in a given randomly chosen 
field. For each animal, multiple sections throughout the length of the muscle were viewed and 3-4 
images analysed per fibre type. H&E stained sections were visualised x20 magnification. Six sections 
were examined across the muscle from the rostral, middle and caudal regions. Two randomly selected 
areas were captured per muscle section from non-overlapping areas for analysis. Muscle pathology 
was scored using ImageJ software. The number of myofibres displaying central nucleation was 
expressed as a percentage of the total number of myofibres per image. Putative inflammatory cell 
infiltration (the presence of cells in the extracellular matrix), was also scored and expressed as a 
percentage of the total area of muscle. For Masson’s trichrome staining, the microscope lighting 
exposure was maintained throughout.  Three sections, with two images captured per section, from the 
mid-portion of the muscle, were analysed per animal. Images were analysed using a colour balance 
threshold (ImageJ software), and the area of collagen was expressed as a percentage of the total area 
of muscle. For chemokine analysis, chemokine signals within the detectable range were expressed as 
relative fluorescence units per μg protein (RFU/μg protein), with equal protein loading in all wells. 
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2.7 Statistical Analysis  
Values are expressed as mean ± S.D. Muscle functional data were statistically compared using two-
way ANOVA (genotype x treatment) with Bonferroni post-hoc test. For muscle histology, group 
means were generated from multiple images averaged per animal and then compared by two-way 
ANOVA (genotype x treatment) with Bonferroni post-hoc test. P < 0.05 was deemed to be statistically 
significant.  
3. Results 
3.1 Body mass 
There was a significant difference in body mass (p < 0.0001; two-way ANOVA) between 
age-matched WT and mdx mice; the latter were slightly heavier. Drug treatment had no effect 
on body mass. 
 
3.2 Isometric force and twitch contractile kinetics 
Table 1 shows data for sternohyoid muscle twitch force and contractile kinetics (CT and ½ 
RT) from animals following drug or saline treatment. Mdx sternohyoid twitch force was 
significantly lower  (p = 0.01 (genotype); two-way ANOVA) compared with WT. Post hoc 
analysis revealed that drug treatment significantly increased twitch force in mdx sternohyoid 
(p < 0.01; two-way ANOVA with Bonferroni), but not in WT (p > 0.05). There was no 
significant difference between WT and mdx in values for CT and ½ RT; both were unaffected 
by drug treatment. Although statistical differences were not observed for CT and ½ RT across 
groups, sizeable effects were noticed which could have physiological relevance. CT was 
increased by ~45% and ½ RT by ~28% for mdx sternohyoid compared with WT. Treatment 
reduced CT by ~18% and ½ RT by ~19% in mdx mice. Peak force at 100Hz was significantly 
lower in mdx sternohyoid (p = 0.0003) compared with WT (Fig. 1). Post hoc analysis showed 
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that drug treatment significantly increased force for WT (p < 0.01) and mdx (p < 0.01) 
sternohyoid. 
 
3.3 Isotonic contractile parameters and kinetics 
Table 1 shows data for sternohyoid muscle isotonic contractile parameters: Wmax, Pmax, 
Smax and Vmax. Wmax was significantly reduced in mdx sternohyoid (p = 0.004; two-way 
ANOVA) compared with WT. Drug treatment significantly increased Wmax for WT (p < 
0.05; two-way ANOVA with Bonferroni), but not mdx muscle (p > 0.05). Pmax was 
significantly reduced in mdx sternohyoid (p = 0.0003) compared with WT, and drug 
treatment significantly increased Pmax in mdx (p = 0.01). Vmax was significantly reduced in 
mdx sternohyoid (p = 0.008) compared with WT, and this was unaffected by drug treatment. 
There was no significant difference in Smax between WT and mdx. Drug treatment had no 
effect on Smax in both groups. 
 
3.4 Isotonic load relationships 
Fig. 2 (A-D) shows data for sternohyoid muscle isotonic load relationships. Loading had a 
significant effect on work (p < 0.0001; two-way ANOVA; Fig. 2A), power (p < 0.0001; Fig. 
2B), shortening (p < 0.0001; Fig. 2C) and shortening velocity (p < 0.0001; Fig. 2D) for both 
WT and mdx sternohyoid. Mdx muscle had significantly reduced work (p < 0.0001), power (p 
< 0.0001) and shortening velocity (p < 0.0001) compared with WT. Drug treatment 
significantly increased work production for WT (p < 0.0001; two-way ANOVA with 
Bonferroni) and mdx muscle (p < 0.0001). Power production was also significantly increased 
for WT (p < 0.0001) and mdx (p < 0.0001) sternohyoid following drug treatment. Shortening 
velocity was significantly increased for mdx muscle (p = 0.02) following drug treatment. 
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3.5 MHC fibre type distribution 
Type I fibres were absent from sternohyoid muscle in all groups. A positive control image for 
type I fibre staining in WT mouse diaphragm muscle is shown in Fig. 3A. The fibre type 
distribution of type IIa fibres did not vary significantly between the four groups (Fig. 3B). 
For mdx saline, the distribution of type IIx fibres was significantly increased compared with 
WT saline (Fig. 3C; p < 0.0001; two-way ANOVA), whereas the distribution of type IIb 
fibres was significantly reduced in mdx saline compared with WT saline (Fig. 3D; p < 0.01). 
Sternohyoid fibre type changes were prevented/reversed by drug treatment in mdx with 
significant changes in type IIx (Fig. 3C; p < 0.01; two-way ANOVA with Bonferrroni) and 
type IIb fibres (Fig. 3D; p < 0.05) compared with mdx saline.  
 
 3.6 Fibre cross-sectional area  
Figure 3E shows data for the CSA for all fibre types. There was a significant increase in the 
CSA of type IIa (p < 0.05; two-way ANOVA) and type IIx fibres (p < 0.05) in mdx 
sternohyoid compared with WT. Drug treatment had no significant effect on type IIa (p = 
0.08) or type IIx (p = 0.628) CSA for both WT and mdx. The CSA of type IIb fibres were not 
significantly different between WT and mdx. With treatment, type IIb CSA was significantly 
increased in WT only (p < 0.05; two-way ANOVA with Bonferroni).  
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3.7 Central nucleation and putative inflammatory cell infiltration  
The percentage of sternohyoid muscle fibres with centrally located nuclei was significantly 
increased in mdx (Fig 4A-B; p < 0.0001; two-way ANOVA) compared with WT sternohyoid. 
Central nucleation was reduced slightly in mdx mice following drug treatment compared with 
mdx saline (Fig 4A-B; p < 0.05; two-way ANOVA with Bonferroni). The areal density of 
inflammatory cell infiltration was significantly increased in mdx sternohyoid muscle (Fig 
4A+C; p < 0.001; two-way ANOVA) compared with WT. Drug treatment had no significant 
effect on the relative area of putative immune cell infiltration (Fig 4A+C). 
3.8 Collagen content 
Masson’s trichrome staining was applied to investigate muscle collagen content between 
groups. The percentage area of collagen was significantly increased in mdx sternohyoid 
compared with WT (Fig. 5A+B; p = 0.0103; two-way ANOVA). Drug treatment had no 
significant effect on collagen content for both WT (p > 0.05) and mdx (p > 0.05) sternohyoid. 
 
3.9 Chemokines  
Figure 6 shows data for chemokine content in sternohyoid muscle from WT and mdx mice 
following drug or saline treatment. MIP-2, IP-10 and MIP-3α were significantly increased in 
the mdx sternohyoid (p < 0.0002, MIP-2 and IP-10; p = 0.004, MIP-3α; two-way ANOVA) 
compared with WT controls. Post-hoc analysis revealed that drug treatment significantly 
increased MIP-2, IP-10 and MIP-3α in mdx sternohyoid (p < 0.0001, MIP-2 and IP-10; p < 
0.01 MIP-3α; two-way ANOVA with Bonferroni), but not in WT mice (p> 0.05, Fig. 6A-C). 
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4. Discussion 
The key findings of the present study are: (1) Sternohyoid muscle weakness in mdx mice is 
evidenced by reduced specific force and power output; (2) Sternohyoid weakness is 
associated with changes in myosin heavy chain isoform expression, with an increase in the 
abundance of type IIx and a concomitant decrease in type IIb fibres; (3) The incidence of 
centrally-nucleated muscle fibres, percentage and areal density of inflammatory cell 
infiltrates, and deposition of collagen was significantly increased in mdx sternohyoid; (4) 
Chemokines were significantly increased in mdx sternohyoid; (5) Co-treatment with the xIL-
6R antibody and Uro-2 restored mechanical force and power production in mdx sternohyoid 
muscle; (6) Drug treatment significantly prevented or reversed fibre transitions in mdx 
sternohyoid, reduced the proportion of centrally nucleated fibres, but did not affect the total 
area of putative inflammatory cell infiltration, or collagen content within mdx muscle; (7) 
Drug treatment significantly increased chemokines in mdx sternohyoid muscle. 
Chronic respiratory insufficiency is a cardinal feature of DMD. The diaphragm is severely 
affected, with muscle fibre degeneration and fibrosis central characteristics of the disease (De 
Bruin et al., 1997). DMD patients often suffer from SDB, with episodes of hypoventilation 
during sleep, associated with aberrant blood gas disturbances, necessitating ventilator use at 
later stages to maintain respiratory function, (Hukins & Hillman, 2000).  
The mdx mouse, a dystrophin deficient model (Bulfield et al., 1984), has been studied 
extensively to understand the pathophysiology of DMD and has also served as a pre-clinical 
model for the study of pharmacological treatment strategies (Manning & O'Malley, 2015). As 
DMD progresses, cardiopulmonary failure is the leading cause of death (Hukins & Hillman, 
2000). The dystrophin deficient mdx mouse has a milder phenotype than DMD patients in the 
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context of cardiac and limb muscle. In contrast, the respiratory muscles, including the 
sternohyoid muscle, show severe mechanical weakness at a young age in the mdx mouse 
(Burns & O'Halloran, 2016). Dystrophic diaphragm muscle undergoes repetitive cycles of 
degeneration and regeneration, with additional activation of inflammatory cascades that 
further exacerbate muscle weakness. Whilst diaphragm muscle function has been well 
characterised in DMD (De Bruin et al., 1997), and the mdx mouse (Coirault et al., 1999; 
Coirault et al., 2003; Bates et al., 2013), little is known about the complementary muscles of 
breathing, especially the airway dilator muscles of the pharynx that are critical in the control 
of airway calibre, which is surprising given the prevalence of SDB in DMD boys (Bersanini 
et al., 2012). 
In the present study, we demonstrate that mdx sternohyoid muscle shows impaired 
performance at 8 weeks of age, consistent with our recent report (Burns & O'Halloran, 2016). 
This functional impairment is characterised by reduced specific force (twitch and tetanic 
contractions), reduced maximum mechanical work and power production, and reduced 
Vmax. Work and power production as a function of load bearing was significantly reduced 
for mdx saline compared with WT saline. We observed a ~44% decrease in sternohyoid 
muscle peak tetanic force for mdx saline versus WT saline, which is consistent with previous 
findings (Attal et al., 2000; Burns & O'Halloran, 2016). These studies reveal severe 
mechanical dysfunction in sternohyoid muscle from young and aged mdx mice suggesting 
that upper airway obstruction in DMD may be a result of increased collapsibility of the 
pharyngeal airway arising from dysfunction of upper airway dilator muscles.  
Sternohyoid muscle weakness in mdx was associated with a shift in the myosin heavy chain 
isoform distribution. Contractile performance in muscle correlates with fibre type distribution 
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(Schiaffino & Reggiani, 2011). The sternohyoid muscle is phasically active during respiration 
(Van de Graaff et al., 1984; O'Halloran et al., 2002) and is composed solely of fast fibres 
(type II). Type II fibres display progressively increasing force production from type IIa to IIx 
fibres, with type IIb fibres producing the greatest forces but least resistance to fatigue (Polla 
et al., 2004; Schiaffino & Reggiani, 2011). We observed a significant decrease in the relative 
proportion of type IIb fibres with a concomitant increase in the type IIx fibre count in mdx 
muscle. Since the type IIb fibres are the maximum force producing units with the fastest 
kinetics, this finding is consistent with the functional data demonstrating decreased force-
generating capacity and reduced shortening velocity in mdx compared with WT. Our findings 
are consistent with the observations of others (Attal et al., 2000), who likewise reported 
reduced force-generating capacity and an increased proportion of type IIx and reduced type 
IIb in sternohyoid muscle from aged (6 month) mdx mice. We reason that this shift in the 
fibre type composition of the sternohyoid relates to muscle fibre degeneration and 
regeneration such that the muscle is in a relatively immature state. Muscle fibre remodelling 
will also alter motor neuronal input to the muscle. Since muscle fibre types are determined by 
the motor unit they are innervated by (Mantilla & Sieck, 2003), it is plausible to speculate 
that dystrophic muscle may have an altered motor unit innervation pattern which warrants 
investigation. There is a paucity of information pertaining to the accessory muscles of 
breathing in mdx mice. Unlike the well-characterised mdx diaphragm, the temporal profile of 
mdx sternohyoid muscle structure-function relationship throughout life is unknown, but 
published works suggest that the sternohyoid most likely undergoes a similar pathology to 
mdx diaphragm muscle (Attal et al. 2000; Burns et al. 2016).  
The CSA of a muscle fibre is a determinant of force production. CSA varies between fibres 
increasing from type I fibres to type IIa and IIx, and type IIb (figure 3E). In DMD, the cycles 
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of degeneration and regeneration within muscles leads to alterations in fibre size. As such, 
dystrophic muscle has myofibres of varying size compared to the uniformity of diameter 
found in a normal muscle (Pastoret & Sebille, 1995). Investigation of the CSA of individual 
muscle fibre types revealed that mdx sternohyoid shows evidence of hypertrophied type IIa 
and type IIx fibres. Increasing CSA can be viewed as an adaptive mechanism in the context 
of force production, often observed with resistance training increasing muscle strength. 
However, alterations in fibre size secondary to degeneration and regeneration are 
characteristic of mdx muscle with regeneration producing hypertrophied fibres, which are 
often functionally weaker (Lynch et al., 2001).  
Dystrophic skeletal muscle undergoes progressive cycles of fibre degeneration and 
regeneration following damage, a process that continues until the regenerative capacity is 
exhausted. Skeletal muscle fibre central nucleation is a histological indicator of muscle fibre 
repair and regeneration. We observed a significant increase in the percentage of centrally 
nucleated myofibres in mdx sternohyoid compared with WT, with ~25% of mdx sternohyoid 
fibres presenting with central nuclei. This reveals that sternohyoid muscle from mdx mice is 
undergoing significant muscle damage and repair as early as 8 weeks of age, consistent with 
evidence of severe muscle weakness.  
Inflammation is recognised to be a contributing factor to DMD pathology, which is 
characterised by a persistent inflammatory response in skeletal muscle due to chronic damage 
and stress to functional muscle fibres due to the absence of dystrophin (Deconinck & Dan, 
2007). Inflammatory cell infiltration of damaged and degenerating dystrophic muscle fibres is 
a hallmark feature of skeletal muscle pathology in DMD. Inflammatory cell infiltration has 
been shown to exacerbate myofibre damage in mdx mice (Evans et al., 2009a), with loss of 
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muscle fibres, subsequent fibrosis, and adipose tissue deposition culminating in impaired 
muscle function (Deconinck & Dan, 2007).  We observed a significant increase in putative 
inflammatory cell infiltration in young mdx sternohyoid muscle, typically thought to be 
associated with muscle damage and subsequent regeneration. Enhanced inflammatory cell 
infiltrate drives a fibrotic environment (Pelosi et al., 2015b). Indeed, we observed a 
significant increase in the collagen content of the mdx sternohyoid. Fibrosis is well 
characterised in the diaphragm of mdx mice (Stedman et al., 1991), but to our knowledge this 
is the first report of enhanced collagen deposition in a complementary muscle of breathing, 
the sternohyoid. Enhanced collagen deposition within the muscle impairs muscle functional 
performance, which given the role of the sternohyoid as an airway dilator has implications for 
adequate control of airway calibre in DMD.    
DMD patients and the mdx mouse have elevated levels of circulating pro-inflammatory 
cytokines, namely IL-1, IL-6 and TNFα (Gosselin & Williams, 2006), promoting an 
inflammatory response associated with dystrophic changes (Kumar & Boriek, 2003). Anti-
inflammatory treatment with glucocorticoids is the main treatment strategy in delaying loss of 
ambulation in DMD but treatment is unfortunately associated with deleterious side effects 
(Pichavant et al., 2011). Therefore, there is a need for new therapeutic strategies that can 
rescue or at least halt muscle impairments in DMD.  
IL-6 is a pleiotropic cytokine, exhibiting both pro and anti-inflammatory properties, hence 
mediating diverse biological functions (Pedersen & Febbraio, 2008). Several studies have 
targeted pro-inflammatory cytokine signalling in mdx and examined their respective roles in 
the dystrophic process. TNF-α inhibition has been shown to have beneficial effects in mdx 
mice (Messina et al., 2006; Messina et al., 2009). IL-6 has been shown to promote muscle 
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atrophy in rats (Haddad et al., 2005) and mice (Tsujinaka et al., 1996), which is amenable to 
blockade. Additionally, mdx mice crossed with mice overexpressing IL-6, present with a 
significant reduction in limb muscle force and a decline in performance during treadmill 
exercise, indicative of impaired muscle function (Pelosi et al., 2015b). Treatment with an 
xIL-6R antibody, blocking IL-6 signalling, has been shown to decrease pro-inflammatory 
cytokine expression in the diaphragm, improving treadmill performance in mdx mice (Pelosi 
et al., 2015b).  
In the present study, co-administration of an IL-6 neutralising antibody (xIL-6R) and a 
CRFR2 agonist (Uro-2) in mdx mice resulted in significantly increased force-generating 
capacity compared with mdx mice treated with saline (~86% increase). Specific force in mdx 
sternohyoid following treatment was increased to values equivalent to WT saline. Drug 
treatment increased mdx sternohyoid work, power and shortening velocity over the load 
continuum (0-60% max tension). Increased work production following treatment in mdx is 
due to a positive inotropic effect on force-generating capacity since we observed no 
significant difference in peak shortening between mdx treatment and mdx saline. In contrast, 
increased mdx sternohyoid power production is due to both an increase in force-generating 
capacity and shortening velocity. Drug treatment in WT also had a positive inotropic effect 
on force generation (~49% increase) compared with WT saline. For WT, drug treatment 
increased sternohyoid work and power as a function of load bearing, both of which are due to 
an inotropic effect on muscle force. Significant increases in WT sternohyoid specific force 
suggest direct inotropic effects of drug co-treatment on sternohyoid muscle fibres. However, 
it should be noted that we determined tissue, and not fibre, CSA for our calculation of 
specific force. Therefore, whilst our measurement accounts for force normalised to tissue 
CSA, it does not account for alterations in myofibre CSA, which contribute to force-
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generation in muscle. This is an important distinction since drug co-treatment caused fibre 
hypertrophy in WT (but not mdx) muscle. Uro-2 elevates cAMP, protein kinase A and the 
cAMP-binding protein Epac (Reutenauer-Patte et al., 2012), and improves calcium 
homeostasis in calcium over-loaded mdx striated muscle with beneficial protective effects 
reducing muscle necrosis (Reutenauer-Patte et al., 2012). CRFR2 agonists increase muscle 
fibre mass, with evidence of increased muscle fibre CSA and absolute muscle force (Hinkle 
et al. 2004), in addition to actions that prevent atrophying of muscle in various experimental 
models (Hinkle et al., 2003, 2004). As such, we posit that fibre hypertrophy likely 
contributed to enhanced force generation in WT sternohyoid. It remains unclear however, if 
drug co-treatment exerted direct inotropic effects on myofibres contributing to muscle force. 
Of interest, direct positive inotropic effects of Uro-2 have been noted in the treatment of heart 
failure (Bale et al, 2004) and Uro-2 has been shown to exert a positive inotropic effect in the 
isolated rat heart through cAMP-dependent mechanisms (Calderon-Sanchez et al., 2009), a 
major regulator of skeletal muscle contractility (Berdeaux et al., 2012).  
Drug treatment in mdx mice significantly reduced type IIx and increased type IIb fibre 
distribution compared with untreated mdx saline. As such, drug treatment restored/ prevented 
fibre type transitions that are evident in the mdx saline group compared with WT saline. The 
preservation of type IIb fibres is likely contributing to the restoration of muscle force in mdx 
sternohyoid. Conversely, there was no difference in the distribution of any fibre type in the 
WT drug treatment group compared with WT saline. Uro-2 has been shown to induce 
anabolism in skeletal muscle (Reutenauer-Patte et al., 2012). Anabolism in fibres supports 
increased force production, which could be beneficial to the dystrophic muscles of mdx mice. 
Interestingly, we observed hypertrophy of type IIb fibres in WT sternohyoid, but not mdx 
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sternohyoid following drug treatment, revealing a different structural basis for improved 
force comparing WT (hypertrophy) to mdx (fibre preservation).   
Drug treatment in mdx slightly ameliorated sternohyoid muscle fibre central nucleation 
compared with mdx saline; conversely, percentage central nucleation was unaffected by 
treatment in WT sternohyoid. This suggests that drug treatment suppressed muscle fibre 
damage, resulting in fewer necrotic fibres, which should be beneficial for muscle 
performance. This observation highlights that muscle fibre preservation (and maturation to 
type IIb) is likely an important contributor to force generation in mdx-treated muscles in our 
study. However, of interest, drug treatment had no effect on collagen content or putative 
immune cell infiltration in mdx sternohyoid. As such, drug treatment was ineffective in 
reducing muscle fibrosis, perhaps resulting from muscle inflammation. As we did not 
characterise the nature of the infiltrate area (which we concede will also include non-immune 
cell types), we are unable to determine if drug treatment altered the cellular milieu in the 
interstitial spaces between myofibres. Chemokines were significantly increased in mdx 
sternohyoid muscle which is consistent with previous reports of elevated chemokines in 
muscle from mdx mice (Porter et al., 2003; Demoule et al., 2005). Interestingly, drug 
treatment in mdx significantly increased the content of chemo-attractant agents, suggesting 
that there may follow a heightened immune response in mdx muscle following drug 
treatment. Such a response could act to recruit immune cells to repair damaged muscle fibres, 
and thus lead to functional improvements in sternohyoid muscle, perhaps contributing to the 
impressive force recovery observed in our study.  
From the present work we cannot ascertain which of the two drug treatments is responsible 
for the inotropic and structural effects observed in WT and mdx mice. Recent work 
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investigated the individual roles of xIL-6R and Uro-2 in improving mdx diaphragm force 
(Manning et al., 2017). Of relevance to the current study, Manning et al. (2017) revealed an 
additive effect of xIL-6R and Uro-2 co-treatment on diaphragm muscle force providing the 
rationale for our combined drug approach. Additional studies describing the cellular 
mechanisms whereby xIL-6R and Uro-2 improve sternohyoid muscle function are warranted. 
Our relatively short (2 week) intervention has yielded impressive findings, preserving 
sternohyoid muscle force-generating capacity in mdx mice. Although there are no temporal 
studies of the mdx sternohyoid during development to adulthood, the drug treatment began at 
a time when significant muscle remodelling is likely to be under way (based on work in mdx 
diaphragm (Coirault et al., 2003). Intervention at a younger age and for a longer treatment 
duration would be an interesting study to explore the efficacy of the drug treatment before 
onset of muscle necrosis. It would also be of interest to determine if performance is preserved 
in older animals following treatment and if there are any adverse side effects due to 
prolonged drug treatment. Although drug treatment fully restored sternohyoid muscle force, 
there was no difference in the relative area of infiltration in the mdx sternohyoid drug-
treatment group compared with mdx saline. Our data suggest that the beneficial effect of drug 
treatment on sternohyoid muscle fibre form and function is achieved without any apparent 
influence on local muscle inflammation and fibrosis, linked to on-going muscle fibre damage 
and repair. This suggests that the beneficial effect of the drug therapy relates to a retardation 
in muscle fibre damage allowing maturation of functional fibres, but without overt changes in 
muscle infiltrate. However, it is important to note that the nature of the inflammatory 
infiltrate may be favourably altered by drug treatment. Macrophages can exist in one of two 
states, M1 or M2. While M2 macrophages contribute to muscle repair, M1 macrophages can 
increase muscle fibre lysis (Villalta et al., 2015). Therefore, depending on the state of the 
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infiltrating macrophage, inflammation can result in adaptive or maladaptive processes 
promoting regeneration or driving muscle wasting. We did not characterise the nature of the 
infiltrate in mdx muscle and therefore we cannot comment on the effect of drug treatment on 
the immune cell signature in mdx muscle. This requires further investigation, especially in the 
light of our observation that chemokines were increased in mdx and further increased by drug 
treatment, which may have established a beneficial immune response that favoured muscle 
performance. We also acknowledge that IL-6 blockade may have arrested beneficial actions 
of the myokine in muscle such as promoting myoblast proliferation and myotube formation.  
In summary, mdx sternohyoid shows evidence of severe mechanical dysfunction and fibre 
type immaturity at an early age. Co-treatment with an anti-IL-6 receptor antibody and CRF-2 
receptor agonist (Uro-2) had a positive inotropic effect, restoring mechanical force and power 
in dystrophic sternohyoid muscle. Drug treatment preserved fibre complement in mdx 
sternohyoid and slightly ameliorated the proportion of fibres with evidence of central 
nucleation indicative of damage. Preservation of MHC type IIb fibres as well as a partial 
reduction in centronucleation suggesting a preservation of functional fibres may underpin, at 
least in part, recovery of force production in the mdx drug-treated mice. Following a 
relatively short drug intervention period, recovery of contractile function was impressive in 
our study highlighting the potential utility of this combination therapy in DMD. 
 
 
 
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
Acknowledgements  
DPB was supported by funding from the Department of Physiology, UCC. The monoclonal 
anti-IL-6 receptor antibody was gifted by Chugai Pharmaceuticals, Tokyo, Japan. We are 
grateful to staff of the Biological Services Unit, UCC for support with animal care and 
welfare. We are grateful to Dr. G. Jasionek, Department of Physiology, UCC for technical 
support. 
Disclosures  
The authors have no financial, professional or personal conflicts relating to this publication. 
 
Author contributions 
DPB: experimental design; acquisition of data; analysis and interpretation of data; drafting of 
the original manuscript; JR: acquisition of data; analysis; LC: acquisition of data; analysis; 
KM: acquisition of data; analysis; MB: acquisition of data; analysis; DOM: experimental 
design; critical revision of the manuscript for important intellectual content; KOH: 
experimental design; interpretation of data; drafting and critical revision of the manuscript for 
important intellectual content; DE: experimental design; data acquisition; interpretation of 
data; drafting and critical revision of the manuscript for important intellectual content.  
 
 
 
 
 
 
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
5. References 
Attal P, Lambert F, Marchand-Adam S, Bobin S, Pourny JC, Chemla D, Lecarpentier Y & Coirault C 
(2000). Severe mechanical dysfunction in pharyngeal muscle from adult mdx mice. Am J 
Respir Crit Care Med 162, 278-281. 
 
Barbé F, Quera-Salva MA, McCann C, Gajdos P, Raphael JC, de Lattre J & Agustí AG (1994). Sleep-
related respiratory disturbances in patients with Duchenne muscular dystrophy. Eur Respir J 
7, 1403-1408. 
 
Bates G, Sigurdardottir S, Kachmar L, Zitouni NB, Benedetti A, Petrof BJ, Rassier D & Lauzon AM 
(2013). Molecular, cellular, and muscle strip mechanics of the mdx mouse diaphragm. Am J 
Physiol Cell Physiol 304, C873-880. 
 
Beck J, Weinberg J, Hamnegård CH, Spahija J, Olofson J, Grimby G & Sinderby C (2006). 
Diaphragmatic function in advanced Duchenne muscular dystrophy. Neuromuscul Disord 16, 
161-167. 
 
Bersanini C, Khirani S, Ramirez A, Lofaso F, Aubertin G, Beydon N, Mayer M, Maincent K, Boulé M & 
Fauroux B (2012). Nocturnal hypoxaemia and hypercapnia in children with neuromuscular 
disorders. Eur Respir J 39, 1206-1212. 
 
Bulfield G, Siller WG, Wight PA & Moore KJ (1984). X chromosome-linked muscular dystrophy (mdx) 
in the mouse. Proc Natl Acad Sci U S A 81, 1189-1192. 
 
Burns DP, Edge D, O'Malley D & O'Halloran KD (2015). Respiratory Control in the mdx Mouse Model 
of Duchenne Muscular Dystrophy. Adv Exp Med Biol 860, 239-244. 
 
Burns DP & O'Halloran KD (2016). Evidence of hypoxic tolerance in weak upper airway muscle from 
young mdx mice. Respir Physiol Neurobiol 226, 68-75. 
 
Coirault C, Lambert F, Marchand-Adam S, Attal P, Chemla D & Lecarpentier Y (1999). Myosin 
molecular motor dysfunction in dystrophic mouse diaphragm. Am J Physiol 277, C1170-1176. 
 
Coirault C, Pignol B, Cooper RN, Butler-Browne G, Chabrier PE & Lecarpentier Y (2003). Severe 
muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J Appl 
Physiol (1985) 94, 1744-1750. 
 
De Bruin PF, Ueki J, Bush A, Khan Y, Watson A & Pride NB (1997). Diaphragm thickness and 
inspiratory strength in patients with Duchenne muscular dystrophy. Thorax 52, 472-475. 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
Deconinck N & Dan B (2007). Pathophysiology of duchenne muscular dystrophy: current hypotheses. 
Pediatr Neurol 36, 1-7. 
 
Demoule A, Divangahi M, Danialou G, Gvozdic D, Larkin G, Bao W & Petrof BJ (2005). Expression and 
regulation of CC class chemokines in the dystrophic (mdx) diaphragm. Am J Respir Cell Mol 
Biol 33, 178-185. 
 
Emery AE (1991). Population frequencies of inherited neuromuscular diseases--a world survey. 
Neuromuscul Disord 1, 19-29. 
 
Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J & Grange RW (2009a). Dysregulated 
intracellular signaling and inflammatory gene expression during initial disease onset in 
Duchenne muscular dystrophy. Am J Phys Med Rehabil 88, 502-522. 
 
Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J & Grange RW (2009b). Immune-mediated 
mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy 
and provide targets for therapeutic intervention. PM R 1, 755-768. 
 
Gosselin LE & Williams JE (2006). Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) 
diaphragm muscle. Muscle Nerve 33, 820-823. 
 
Haddad F, Zaldivar F, Cooper DM & Adams GR (2005). IL-6-induced skeletal muscle atrophy. J Appl 
Physiol (1985) 98, 911-917. 
 
Hall JE, Kaczor JJ, Hettinga BP, Isfort RJ & Tarnopolsky MA (2007). Effects of a CRF2R agonist and 
exercise on mdx and wildtype skeletal muscle. Muscle Nerve 36, 336-341. 
 
Hill NS, Redline S, Carskadon MA, Curran FJ & Millman RP (1992). Sleep-disordered breathing in 
patients with Duchenne muscular dystrophy using negative pressure ventilators. Chest 102, 
1656-1662. 
 
Hinkle RT, Donnelly E, Cody DB, Bauer MB & Isfort RJ (2003). Urocortin II treatment reduces skeletal 
muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle 
mass and function. Endocrinology 144, 4939-4946. 
 
Hukins CA & Hillman DR (2000). Daytime predictors of sleep hypoventilation in Duchenne muscular 
dystrophy. Am J Respir Crit Care Med 161, 166-170. 
 
Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA & Pedersen BK (2000). Muscle contractions 
induce interleukin-6 mRNA production in rat skeletal muscles. J Physiol 528 Pt 1, 157-163. 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
Kumar A & Boriek AM (2003). Mechanical stress activates the nuclear factor-kappaB pathway in 
skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 17, 386-396. 
 
Lewis P, Sheehan D, Soares R, Coelho AV & O'Halloran KD (2016). Redox Remodeling Is Pivotal in 
Murine Diaphragm Muscle Adaptation to Chronic Sustained Hypoxia. Am J Respir Cell Mol 
Biol 55, 12-23. 
 
Lewis P, Sheehan D, Soares R, Varela Coelho A & O'Halloran KD (2015). Chronic sustained hypoxia-
induced redox remodeling causes contractile dysfunction in mouse sternohyoid muscle. 
Front Physiol 6, 122. 
 
Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV & Faulkner JA (2001). Force and power output of fast 
and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 535, 591-600. 
 
Manning J, Buckley MM, O'Halloran KD & O'Malley D (2016). In vivo neutralization of IL-6 receptors 
ameliorates gastrointestinal dysfunction in dystrophin-deficient mdx mice. 
Neurogastroenterol Motil 28, 1016-1026. 
 
Manning J, Buckley MM, O'Halloran KD & O'Malley D (2017). Combined xIL-6R and urocortin-2 
treatment restores mdx diaphragm muscle force. Muscle Nerve. 
 
Manning J & O'Malley D (2015). What has the mdx mouse model of duchenne muscular dystrophy 
contributed to our understanding of this disease? J Muscle Res Cell Motil. 
 
Mantilla CB & Sieck GC (2003). Invited review: Mechanisms underlying motor unit plasticity in the 
respiratory system. J Appl Physiol (1985) 94, 1230-1241. 
 
Messina S, Bitto A, Aguennouz M, Mazzeo A, Migliorato A, Polito F, Irrera N, Altavilla D, Vita GL, 
Russo M, Naro A, De Pasquale MG, Rizzuto E, Musarò A, Squadrito F & Vita G (2009). 
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a 
comparison study with methylprednisolone. Exp Neurol 220, 349-358. 
 
Messina S, Bitto A, Aguennouz M, Minutoli L, Monici MC, Altavilla D, Squadrito F & Vita G (2006). 
Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle 
function in Mdx mice. Exp Neurol 198, 234-241. 
 
Messina S, Vita GL, Aguennouz M, Sframeli M, Romeo S, Rodolico C & Vita G (2011). Activation of NF-
kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol 30, 16-23. 
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
Moran EM & Mastaglia FL (2014). Cytokines in immune-mediated inflammatory myopathies: cellular 
sources, multiple actions and therapeutic implications. Clin Exp Immunol 178, 405-415. 
 
Nowak KJ & Davies KE (2004). Duchenne muscular dystrophy and dystrophin: pathogenesis and 
opportunities for treatment. EMBO Rep 5, 872-876. 
 
O'Halloran KD (2006). Effects of nicotine on rat sternohyoid muscle contractile properties. Respir 
Physiol Neurobiol 150, 200-210. 
 
O'Halloran KD, McGuire M, O'Hare T & Bradford A (2002). Chronic intermittent asphyxia impairs rat 
upper airway muscle responses to acute hypoxia and asphyxia. Chest 122, 269-275. 
 
O'Leary AJ & O'Halloran KD (2016). Diaphragm muscle weakness and increased UCP-3 gene 
expression following acute hypoxic stress in the mouse. Respir Physiol Neurobiol 226, 76-80. 
 
Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K & Mihara M (2002). Characterization of anti-mouse 
interleukin-6 receptor antibody. Immunol Lett 84, 231-240. 
 
Pastoret C & Sebille A (1995). Age-related differences in regeneration of dystrophic (mdx) and 
normal muscle in the mouse. Muscle Nerve 18, 1147-1154. 
 
Pedersen BK & Febbraio MA (2008). Muscle as an endocrine organ: focus on muscle-derived 
interleukin-6. Physiol Rev 88, 1379-1406. 
 
Pelosi L, Berardinelli MG, De Pasquale L, Nicoletti C, D'Amico A, Carvello F, Moneta GM, Catizone A, 
Bertini E, De Benedetti F & Musarò A (2015a). Functional and Morphological Improvement 
of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMedicine 2, 285-293. 
 
Pelosi L, Berardinelli MG, Forcina L, Spelta E, Rizzuto E, Nicoletti C, Camilli C, Testa E, Catizone A, De 
Benedetti F & Musarò A (2015b). Increased levels of interleukin-6 exacerbate the dystrophic 
phenotype in mdx mice. Hum Mol Genet 24, 6041-6053. 
 
Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, 
Wooddell CI, Xiao X & Tremblay JP (2011). Current status of pharmaceutical and genetic 
therapeutic approaches to treat DMD. Mol Ther 19, 830-840. 
 
Polla B, D'Antona G, Bottinelli R & Reggiani C (2004). Respiratory muscle fibres: specialisation and 
plasticity. Thorax 59, 808-817. 
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
Porter JD, Guo W, Merriam AP, Khanna S, Cheng G, Zhou X, Andrade FH, Richmonds C & Kaminski HJ 
(2003). Persistent over-expression of specific CC class chemokines correlates with 
macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 13, 223-235. 
 
Reutenauer-Patte J, Boittin FX, Patthey-Vuadens O, Ruegg UT & Dorchies OM (2012). Urocortins 
improve dystrophic skeletal muscle structure and function through both PKA- and Epac-
dependent pathways. Am J Pathol 180, 749-762. 
 
Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D, Morandi L, De Simone 
M, Rucci N, Bertini E, Bianchi ML, De Benedetti F & Teti A (2011). Mechanisms inducing low 
bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 26, 
1891-1903. 
 
Schiaffino S & Reggiani C (2011). Fiber types in mammalian skeletal muscles. Physiol Rev 91, 1447-
1531. 
 
Smith PE, Edwards RH & Calverley PM (1989). Ventilation and breathing pattern during sleep in 
Duchenne muscular dystrophy. Chest 96, 1346-1351. 
 
Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich 
JM, Sladky JT & Kelly AM (1991). The mdx mouse diaphragm reproduces the degenerative 
changes of Duchenne muscular dystrophy. Nature 352, 536-539. 
Suresh S, Wales P, Dakin C, Harris MA & Cooper DG (2005). Sleep-related breathing disorder in 
Duchenne muscular dystrophy: disease spectrum in the paediatric population. J Paediatr 
Child Health 41, 500-503. 
Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki 
H & Monden M (1996). Interleukin 6 receptor antibody inhibits muscle atrophy and 
modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97, 244-249. 
Van de Graaff WB, Gottfried SB, Mitra J, van Lunteren E, Cherniack NS & Strohl KP (1984). 
Respiratory function of hyoid muscles and hyoid arch. J Appl Physiol 57, 197-204. 
Villalta SA, Rosenberg AS & Bluestone JA (2015). The immune system in Duchenne muscular 
dystrophy: Friend or foe. Rare Dis 3, e1010966. 
White DP & Younes MK (2012). Obstructive sleep apnea. Compr Physiol 2, 2541-2594. 
Whitham M & Febbraio MA (2016). The ever-expanding myokinome: discovery challenges and 
therapeutic implications. Nat Rev Drug Discov. 
Williams R, Lemaire P, Lewis P, McDonald FB, Lucking E, Hogan S, Sheehan D, Healy V & O'Halloran 
KD (2015). Chronic intermittent hypoxia increases rat sternohyoid muscle NADPH oxidase 
expression with attendant modest oxidative stress. Front Physiol 6, 15. 
 
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
Figure Legends: 
 
Figure 1. Peak Isometric Tetanic Force 
Group data (mean ± S.D.) for tetanic force in WT (n=7-8) and mdx (n=7-8) sternohyoid muscle 
following 6 sub-cutaneous injections with saline (0.9% w/v) or treatment (xIL-6R (0.2 mg/kg) and 
Uro-2 (30 μg/kg); co-administered) over two weeks. Peak tetanic force was measured following 
stimulation at 100Hz ex vivo. Data were statistically compared by two-way ANOVA followed by 
Bonferroni post-hoc test.  
** P < 0.01  
Genotype: *** P = 0.0003; treatment P = 0.0001; interaction P = 0.9.  
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Figure 2. Sternohyoid Muscle Isotonic Contractile Properties 
Group data (mean ± S.D.) for work-load (A), power-load (B), shortening-load (C) and shortening 
velocity-load (D) relationships in WT (n=7-8) and mdx (n=7-8) sternohyoid muscle following 6 sub-
cutaneous injections of saline (0.9% w/v) or treatment (xIL-6R (0.2 mg/kg) and Uro-2 (30 μg/kg); co-
administered) over two weeks. Data were statistically compared by two-way ANOVA.  
 
Work: load P < 0.0001; genotype P < 0.0001; WT treatment P < 0.0001; mdx treatment P < 0.0001. 
Power: load P < 0.0001; genotype P < 0.0001; WT treatment P < 0.0001; mdx treatment P < 0.0001. 
Shortening: load P < 0.0001; genotype P = 0.2; WT treatment P = 0.5; mdx treatment P = 0.2.  
Velocity: load P < 0.0001; genotype P < 0.0001; WT treatment P = 0.2; mdx treatment P = 0.002.  
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Figure 3. Sternohyoid Muscle Fibre Distribution and Cross Sectional Area 
Representative immunofluorescence images of Sternohyoid (SH)  muscle fibre type distribution (A), 
showing type IIa fibres (red), type IIx (untagged, appearing black) and type IIb (green) for WT saline 
(top left), mdx saline (top middle), WT drug-treated (bottom left) and mdx drug-treated (bottom 
middle). Note: the mouse sternohyoid muscle is devoid of type I – slow fibres, a positive control from 
type I fibre staining is shown in a section of WT mouse diaphragm (top right).  Scale bars = 200 µm. 
Group data (mean ± S.D.) showing fibre distribution of type IIa fibres (B), type IIx (C) and type IIb 
(D) in WT (n=4) and mdx saline treated mice (n=5), and WT drug-treated (n=4) and mdx drug-treated 
mice (n=4). Mice received 6 sub-cutaneous injections of saline (0.9% w/v) or treatment (xIL-6R (0.2 
mg/kg) and Uro-2 (30 μg/kg); co-administered) over two weeks. Data were statistically compared by 
two-way ANOVA followed by Bonferroni post-hoc test. In mdx mice, type IIx areal density was 
significantly increased (C), whereas type IIb fibre distrubution was decreased (D). With drug 
treatment, type IIx fibre distribution was significantly decreased in mdx mice compared with mdx 
saline (C), while type IIb fibre distribution (D) was increased compared with mdx saline.  
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* P < 0.05; ** P < 0.01.  
B) Genotype P = 0.3; treatment P = 0.3; interaction P = 0.4. 
C) Genotype P = 0.0001; treatment P = 0.007; interaction P = 0.03.  
D) Genotype P = 0.006; treatment P = 0.04; interaction P = 0.1 
Group data (mean ± S.D.) showing mean CSAs of sternohyoid muscle fibre type IIa, type IIx and type 
IIb (E). The CSA of type IIa and type IIx fibres was significantly increased in mdx mice. Drug 
treatment increased the CSA of type IIb fibres in WT mice only.  
Type IIa: Genotype * P = 0.03; treatment P = 0.08; interaction P = 0.5.  
Type IIx: Genotype * P = 0.02; treatment P = 0.6; interaction P =0.8. 
Type IIb: Genotype P = 0.3; treatment: * P = 0.049; interaction P = 0.1. 
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Figure 4. Central Nucleation and Inflammatory Cell Infiltration of Sternohyoid Muscle 
Representative histological images (A) of sternohyoid muscle transverse sections stained with H&E in 
WT saline (top left), mdx saline (bottom left), WT drug-treated (top right) and mdx drug-treated 
(bottom right) scale bars 100 µm. Peripherally located nuclei are apparent in WT saline and WT drug-
treated images. In comparison, mdx mice (saline and drug-treated) displayed an increased incidence of 
centrally located nuclei. Inflammatory cell infiltration is not apparent in WT saline and WT drug-
treated groups. Mdx muscle (saline and treatment) displayed inflammatory cell infiltration, 
highlighted with black arrows. 
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Group data (mean ± S.D.) showing percentage of central nucleation (B) and percentage of infiltration 
of inflammatory cells (C) in sternohyoid muscle from saline-treated WT (n=4-5) and saline-treated 
mdx mice (n=5), and WT (n=4-5) and mdx (n=4-5) mice treated with xIL-6R (0.2 mg/kg) and Uro-2 
(30 µg/kg) given as 6 sub-cutaneous injections over 2 weeks. Data were statistically compared by 
two-way ANOVA followed by Bonferroni post-hoc test. The percentage of centrally nucleated fibres 
was significantly increased in mdx mice. Drug treatment slightly ameliorated central nucleation in 
mdx mice only. The percentage of inflammatory cell infiltrates was significantly increased in mdx 
mice. Drug treatment did not affect this response; p=0.2284 compared with mdx. * p<0.05. 
 
Central nucleation:  Genotype p < 0.0001; treatment p = 0.1; interaction p= 0.02 
Infiltration:   Genotype: *** p = 0.0002, treatment p = 0.2; interaction p = 0.2 
  
  
 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
 
Figure 5. Collagen Deposition in Sternohyoid Muscle 
Representative histological images (A) of sternohyoid muscle transverse sections stained with 
mason’s trichrome in WT saline (top left), mdx saline (bottom left), WT drug-treated (top right) and 
mdx drug-treated (bottom right) scale bars 100 µm. 
Group data (mean ± S.D.) showing percentage of collagen content (B) in sternohyoid muscle from 
saline-treated WT (n=5) and saline-treated mdx mice (n=4), and WT (n=4) and mdx (n=5) mice 
treated with xIL-6R (0.2 mg/kg) and Uro-2 (30 µg/kg) given as 6 sub-cutaneous injections over 2 
weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post-hoc test. 
The percentage of collagen content was significantly increased in mdx mice. Drug treatment had no 
significant effect on collagen content for both WT and mdx. 
 
Genotype: p = 0.0103, treatment: p = 0.0673; interaction p = 0.7779 
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Figure 6. Chemokine Expression in Sternohyoid Muscle 
Values (mean ± S.D.) for macrophage inflammatory protein 2 (MIP-2; A), interferon-γ induced 
protein (IP-10; B) and macrophage inflammatory protein-3 (MIP-3α; C) chemokine expression in 
sternohyoid muscle from WT (n=7-8) and mdx (n=7-8) mice injected sub-cutaneously with saline 
(0.9% w/v) or drug treatment (xIL-6R (0.2mg/kg) and Uro-2 (30μg/kg); co-administered) for two 
weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post-hoc test. 
** p < 0.01; **** p < 0.0001 
 
MIP-2: genotype: p < 0.0001; treatment p < 0.0001; interaction: p < 0.0001 
IP-10: genotype: p = 0.0002; treatment: p = 0.0007; interaction: p = 0.0022 
MIP-3α: genotype: p = 0.0004; treatment: p = 0.0033; interaction: p = 0.0510 
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 WT mdx Two-way ANOVA 
 Saline  
(n=8) 
Treatment  
(n=7) 
Saline  
(n=7) 
Treatment  
(n=8) 
Genotype  Treatment Interaction 
CT (ms) 11.7 ± 
2.0 
12.6 ± 3.4 17.0 ± 
8.8 
13.9 ± 4.3 P = 0.1 P = 0.6 P = 0.3 
½ RT (ms) 18.2 ± 
6.4 
18.0 ± 5.8 23.4 ± 
0.8 
18.8 ± 5.7 P = 0.1 P = 0.2 P = 0.3 
Twitch 
Force 
(N/cm2) 
1.2 ± 
0.4 
1.8 ± 0.6 0.5 ± 
0.3 £ 
1.5 ± 0.8 #  P = 0.01 P = 0.0004 P = 0.5 
Wmax 
(J/cm2) 
0.4 ± 
0.1 
0.6 ± 0.4 $ 0.2 ± 
0.08 
0.3 ± 0.09 P = 0.004 P = 0.01 P = 0.2 
Pmax 
(W/cm2) 
4.7 ± 
1.7 
7.4 ± 3.9 2.1 ± 
1.5 £ 
3.6 ± 0.6 P = 
0.0003 
P = 0.01 P = 0.5 
Smax (L/Lo) 0.3 ± 
0.07 
0.3 ± 0.06 0.3 ± 
0.07 
0.3 ± 0.08 P = 0.3 P = 0.7 P = 0.3 
Vmax (Lo/s) 4.6 ± 
1.8 
4.1 ± 1.5 2.4 ± 
1.1 £ 
3.3 ± 1.2 P = 0.008 P = 0.8 P = 0.2 
 
Table 1. Sternohyoid muscle contractile properties. 
 
Values (mean ± S.D.) for twitch contraction time (CT), twitch half-relaxation time (½ RT), peak 
twitch force, maximum mechanical work (Wmax), maximum mechanical power (Pmax), peak 
shortening (Smax) and peak shortening velocity (Vmax) of sternohyoid muscle from WT (n=7-8) and 
mdx (n=7-8) mice injected sub-cutaneously with saline (0.9% w/v) or drug treatment (xIL-6R 
(0.2mg/kg) and Uro-2 (30μg/kg); co-administered) for two weeks. Data were statistically compared 
by two-way ANOVA followed by Bonferroni post-hoc test. 
 
£ mdx saline significantly different from corresponding WT saline value; p < 0.05 
$ WT treatment significantly different from corresponding WT saline value, p < 0.05  
# mdx treatment significantly different from corresponding mdx saline value, p < 0.05  
